Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to compare the effect of addition of combination of Atorvastatin/CoenzymeQ10 to standard congestive heart failure (CHF) treatment versus addition of Atorvastatin alone on CHF outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Coenzyme Q10 & Atorvastatin | Experimental | 10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months. |
|
| Atorvastatin & placebo | Active Comparator | 10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin | Drug |
| ||
| Coenzyme Q10 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in cardiac Ejection Fraction (EF) | For the determination of change in EF,cardiac EF was determined two times . Baseline :at the beginning of study(before intervention) and the second time after 4 months(after intervention). | Baseline for the first time and after 4 months for the second time |
| Measure | Description | Time Frame |
|---|---|---|
| Change in New York Heart Association Function Class | For the determination of change in New York Heart Association Function Class.it was determined two times .Baseline:at the beginning of study(before intervention)and the second time after 4 months(after intervention). | Baseline for the first time and after 4 months for the second time |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Amin Nemati, MD | Contact | 00989131009918 | nemati@med.mui.ac.ir |
| Name | Affiliation | Role |
|---|---|---|
| Masoud Pourmoghaddas, cardiologist | Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vice Chancellery for Research of Isfahan University of Medical Sciences, Isfahan, Iran | Recruiting | Isfahan | Isfahan | 8174673461 | Iran |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 12, 2016 | |
| Reset | Jul 21, 2016 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 12, 2016 | Jul 21, 2016 |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| C024989 | coenzyme Q10 |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| placebo for coenzyme Q10 | Drug |
|
| D006538 |
| Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |